Center for Bioethics, Harvard Medical School, 641 Huntington Avenue, Boston, MA, 02115, United States; Department of Psychiatry, Massachusetts General Hospital, 55 Fruit Street, Boston, MA, 02114, United States.
Center for Bioethcis and Social Justice, College of Human Medicine, Michigan State University, East Fee Hall 965 Wilson Road Rm A-126, East Lansing, MI, 48824, United States.
Brain Stimul. 2022 Sep-Oct;15(5):1029-1036. doi: 10.1016/j.brs.2022.07.051. Epub 2022 Aug 1.
Clinical trial participants who benefit from experimental neural devices for the treatment of debilitating and otherwise treatment-resistant conditions are generally not ensured continued access to effective therapy or maintenance of devices at the conclusion of trials.
OBJECTIVE/HYPOTHESIS: Post-trial obligations have been extensively examined in the context of drug trials, but there has been little empirical examination of stakeholder perspectives regarding these obligations in the rapidly growing field of neural device research.
This study examined the perspectives of 44 stakeholders (i.e., 23 researchers and 21 patient-participants) involved in implantable neural device trials.
Researchers were concerned about current post-trial management, identified barriers like cost, and suggested ways to improve the system. Many patient-participants were unaware of whether they would have post-trial access, but most thought they should keep devices if beneficial, and agreed with researchers that more should be done to help them keep and maintain these neural devices.
To our knowledge, this is the first in-depth examination of researcher perspectives regarding continued access to experimental neural devices and only the second such examination of patient-participant perspectives. These data can help inform future ethical and policy decisions about post-trial access to implantable neurotechnology.
从治疗致残和其他治疗抵抗性疾病的实验性神经设备中受益的临床试验参与者,通常无法在试验结束时确保继续获得有效治疗或维持设备。
目的/假设:药物试验已经广泛研究了试验后的义务,但在神经设备研究这个快速发展的领域,几乎没有对利益相关者关于这些义务的观点进行实证研究。
本研究调查了 44 名利益相关者(即 23 名研究人员和 21 名患者参与者)参与可植入神经设备试验的观点。
研究人员对当前的试验后管理表示关注,确定了成本等障碍,并提出了改进系统的方法。许多患者参与者不知道他们是否有试验后的使用权,但大多数人认为如果有益,他们应该保留设备,并且与研究人员一致认为,应该采取更多措施帮助他们保留和维护这些神经设备。
据我们所知,这是对研究人员关于继续获得实验性神经设备的看法的首次深入研究,也是对患者参与者的看法的第二次此类研究。这些数据可以帮助为可植入神经技术的试验后使用权做出未来的伦理和政策决策提供信息。